Globus Medical completes acquisition of Nevro Corp. for $5.85/share cash

GLOBUS MEDICAL INC

Completed acquisition of Nevro on April 3, 2025; each Nevro share received $5.85 in cash.
Nevro stock options and RSUs canceled; RSUs converted to cash equal to Merger Consideration.
Acquisition expands Globus's addressable market opportunity to $2 billion in neuromodulation.
Nevro common stock ceased trading on NYSE as of April 3, 2025.
Globus plans to discuss merger benefits during Q1 2025 earnings call in May.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.